Study of Telitacicept and Baricitinib Treatment for Difficult-to-Treat Rheumatoid Arthritis in Adults Aged 18 to 85

What this Trial Is About

This research aims to evaluate the clinical effectiveness and safety of combining telitacicept with baricitinib for patients with difficult-to-treat rheumatoid arthritis D2T RA. It focuses on patients who have not responded adequately to traditional and multiple biological or targeted disease-modifying anti-rheumatic drugs. The study is observational and sponsored by Zhejiang Provincial Peoples Hospital. Participants will receive a combined treatment of telitacicept and baricitinib. This single group treatment approach involves monitoring patients who require this combination due to the ineffectiveness of previous therapies. The study will carefully observe the treatments effects and any adverse events over a period of up to one year. During the study, participants will be regularly assessed for treatment response and safety outcomes. Researchers will track clinical efficacy measures and record any treatment-emergent adverse events. The study will last up to one year, during which patients adherence to the prescribed treatment regimen and overall health will be monitored to ensure comprehensive evaluation of the combined therapy.

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis